Avila Therapeutics, Inc.
Avila Presents Data on Its Novel, Orally-Available Protease Inhibitor, AVL-181, Demonstrating Viral Clearance of Hepatitis C Virus in Preclinical Models
Published in Hepatitis Weekly, November 16th, 2009
Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies. Additionally, using an innovative technology for measuring the extent of covalent bond formation, Avila showed that AVL-181 bonds selectively and irreversibly to HCV protease in vivo in a novel rodent model, thus silencing a key protein necessary for successful viral...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2009-11-16)
More Articles from Hepatitis Weekly
- Henry Ford Health System
Hepatitis B does not increase risk for pancreatic cancer - Hepatitis
Studies from S.K. Roberts et al add new findings in the area of hepatitis - Hepatitis C Virus
New hepatitis C virus research has been reported by scientists at Massachusetts General Hospital - Hepatitis C Virus
Reports from H.S. Ol and co-researchers add new data to research in hepatitis C virus - Hepatitis C Virus
Study results from Mayo Clinic update understanding of hepatitis C virus - Hepatocellular Cancer
Research on hepatocellular cancer discussed by A. Cavazza and co-researchers - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
